[1] Dongiovanni P, Romeo S and Valenti L. Hepatocellular carcinoma innonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol, 2014,20: 12945-12955.
[2] Su CH, Lin Y and Cai L. Genetic factors, viral infection, other factors and livercancer: An update on current progress. Asian Pac J Cancer Prev, 2013, 14: 4953-4960.
[3] Ambros V. The functions of animal microRNAs. Nature, 2004, 431: 350-355.
[4] Bartel DP. Micro RNAs: genomics,biogenesis,mechanism and function. Cell,2004,116: 281-297.
[5] Lai EC. Micro RNAs are complementary to 3′ UTRsequence motifs that mediate negative post-transcrip-tional regulation. Nature Genetics,2002,30: 363-364.
[6] Saxena S,Jonsson ZO,Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off target activity of small inhibitory RNA in mam malian cells.J Biol Chem,2003,278: 44312-44319.
[7] Sun W, Shen W, Yang S, et al. miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β. Cell Res, 2010, 20: 1158-1169.
[8] Kumar V, Palermo R, talora C, et al. Notch and NF-kB signaling pathways regulate miR-223/ FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28: 2324-2335.
[9] Fabris L, Berton S, Citron F, et al. Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35: 4914-4926.
[10] Sun D, Wang C, Long S, et al. C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. Br J Cancer, 2015, 112: 1491-1500.
[11] Dong YW, Wang R, Cai QQ, et al. Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells. J Hepatol, 2014, 60: 792-801.
[12] Laios A, Otoole S, Flavin R,et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer, 2008, 7: 35.
[13] Mangiavacchi A, Fazi F,Racanicehi S,et al. The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA. Oncotarget, 2016, 7: 60155-60168.
[14] Dong Z,Qi R,Guo X,et al.MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. Biochem Biophys Res Commun
[15] Muller F,Ramiro G,Amelia C,et al. Micro RNA-29 family re-verts aberrant methylation in lung cancer by targeting DNA meth-yltransferases 3A an. PNAS,2007,104: 15805-15810.
[16] Xu H,Cheung IY,Guo HF,et al. Micro RNA mi R-29 modulates expression of immunoinhibitory molecule B7-H3: potential impli-cations for immune based therapy of human solid tumors. Cancer Res,2009,69: 6275-6281.
[17] Wang H,Garzon R,Sun H,et al. NF-k B-YY1-mi R-29 regu-latory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell,2008,11: 369-381.
[18] Zhao FY, Yang W, Li, et al. MiR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. Tumour Biol J Int Soc Oncodevelopmental Biol Med, 2017, 39: 1010428317692264.
[19] Cho HJ, Kim SS, Nam JS, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment. Clin Res Hepatol Gastroenterol, 2017, 41: 181-189.
[20] Zhang H, Bai M, Deng T, et al. Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. Cancer Lett, 2016, 375: 331-339.
[21] Hirata H, Ueno K,Shahryari V,et al.MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One, 2013, 8:e55502.
[22] Jiang Y,Chen J,Yue C,et al.The role of miR-182-5p in hepatocarcinogenesis of trichloroethylene in mice.Toxicol Sci, 2017, 156: 208-216.
[23] Huang XH,Chen JS,Wang Q,et al.miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol, 2011, 225:463-472.
[24] Huang XH,Wang Q,Chen JS,et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res, 2009, 39: 786-794.
[25] Yong FL,Law CW,Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer, 2013, 13:280.
[26] Li P, Chen X, Su L,et al. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One, 2013, 8:e66782.
[27] Chen X, Pan M, Han L,et al.miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett, 2013, 587:3729-3737.
[28] Ma YS,Wu TM,Lv ZW,et al.High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1.Oncotarget, 2017, DOI:10.18632/oncotarget.14435
[29] Rottiers V, N r AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol, 2012, 13: 239-250.
[30] Liu P,Zhang H,Liang X,et al.HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.Oncotarget, 2015, 6:29048-29059. |
